Unlock AI-driven, actionable R&D insights for your next breakthrough.

Isopropyl Palmitate As A Pharmaceutical Excipient: Comprehensive Analysis Of Formulation Roles, Stability Enhancement, And Drug Delivery Applications

NOV 17, 202665 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Isopropyl Palmitate (IPP), the ester of isopropyl alcohol and palmitic acid (molecular formula C₁₉H₃₈O₂), has emerged as a multifunctional pharmaceutical excipient with critical roles in drug delivery systems, formulation stability, and rheological control. Beyond its established use in cosmetic and dermatological preparations, IPP demonstrates significant value in pharmaceutical applications ranging from solubilizing agents in parenteral formulations to viscosity modulators in topical and transdermal delivery systems. This article provides an expert-level examination of IPP's physicochemical properties, formulation strategies, regulatory status, and emerging applications in advanced drug delivery platforms, synthesizing patent literature and research findings to guide formulation scientists in optimizing pharmaceutical product performance.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Structure And Physicochemical Properties Of Isopropyl Palmitate In Pharmaceutical Systems

Isopropyl Palmitate is chemically defined as hexadecanoic acid, 1-methylethyl ester, with the structural formula CH₃(CH₂)₁₄COOCH(CH₃)₂ 78. This medium-chain fatty acid ester exhibits a molecular weight of 298.5 g/mol and presents as a clear, colorless to pale yellow liquid at ambient temperature. The compound's amphiphilic character—combining a 16-carbon saturated hydrocarbon chain with an ester linkage to a branched isopropyl group—confers unique solubilization and penetration-enhancing properties essential for pharmaceutical applications.

Key physicochemical parameters relevant to pharmaceutical formulation include:

  • Density: Approximately 0.850–0.855 g/cm³ at 20°C, facilitating ease of handling and volumetric dosing in liquid formulations 78
  • Viscosity: Low dynamic viscosity (5–10 mPa·s at 25°C), enabling rapid spreading and uniform distribution in topical and transdermal systems 16
  • Solubility Profile: Miscible with most organic solvents including ethanol, isopropyl alcohol, and chloroform; practically insoluble in water (<0.01 mg/mL), which necessitates emulsification or co-solvent strategies in aqueous pharmaceutical preparations 410
  • Melting Point: Typically below 0°C, ensuring liquid state across pharmaceutical storage and application temperatures
  • Refractive Index: 1.435–1.438 at 20°C, useful for quality control and identification testing

The ester bond in IPP is susceptible to hydrolysis under extreme pH conditions (pH <3 or >9) and elevated temperatures (>60°C for prolonged periods), which must be considered during formulation development and stability testing 7. However, under typical pharmaceutical storage conditions (pH 4–8, 15–30°C), IPP demonstrates excellent chemical stability with shelf lives exceeding 24 months when protected from light and moisture.

Formulation Roles And Concentration Optimization In Drug Delivery Systems

Solubilizing Agent And Co-Solvent Functions

Isopropyl Palmitate serves as an effective solubilizing agent for lipophilic active pharmaceutical ingredients (APIs) in both oral and parenteral formulations. Patent literature demonstrates IPP's utility in drug delivery compositions at concentrations ranging from 1 wt% to 70 wt%, with optimal performance typically observed between 5–12 wt% for most applications 410. In transdermal and topical formulations, IPP concentrations above 5 wt% significantly enhance the solubility of poorly water-soluble drugs, while concentrations exceeding 20 wt% may compromise formulation stability due to phase separation or excessive oiliness 4.

Specific concentration guidelines from patent formulations include:

  • Transdermal Delivery Systems: 5–15 wt% IPP combined with 15–50 wt% C₂₋₄ alcohols (ethanol, isopropyl alcohol) to achieve optimal API solubilization and skin permeation 410
  • Parenteral Solutions: 2–10 wt% IPP as a co-solvent with polyoxyethylene castor oil derivatives (200–2,000 parts per part of API) for injectable formulations requiring enhanced drug stability 511
  • Ophthalmic Preparations: Ultra-low concentrations (0.0003–0.01% w/v of API) with IPP-compatible surfactants to maintain ocular tolerability while ensuring therapeutic efficacy 91112

The synergistic combination of IPP with C₂₋₄ alcohols (particularly ethanol at 20–70 wt%) creates a co-solvent system that dramatically improves the dissolution kinetics of crystalline APIs, reducing particle size and enhancing bioavailability 410. This approach is particularly valuable for BCS Class II and IV compounds where solubility limitations constrain therapeutic performance.

Rheological Modifier And Viscosity Control

A distinctive pharmaceutical application of Isopropyl Palmitate lies in its ability to modulate formulation viscosity without requiring traditional thickening agents or gelling polymers. Patent US251fc2ae (Beiersdorf AG) demonstrates that IPP can adjust the rheology of emulsion-based preparations through its influence on internal phase structure and interfacial properties 16. This mechanism operates through:

  • Interfacial Film Modification: IPP molecules orient at oil-water interfaces in emulsions, altering interfacial tension and droplet coalescence kinetics, thereby controlling bulk viscosity 16
  • Internal Phase Volume Adjustment: By serving as the dispersed phase or co-dispersed phase component, IPP concentration directly influences the volume fraction of the internal phase, which exponentially affects viscosity according to the Krieger-Dougherty equation 1
  • Lamellar Structure Disruption: In certain emulsion systems, IPP can disrupt rigid lamellar gel networks formed by emulsifiers, reducing viscosity and improving spreadability 6

Practical formulation strategies include using IPP at 3–8 wt% to reduce viscosity in thick creams (from 50,000–100,000 cP to 10,000–30,000 cP), improving patient compliance and application uniformity 16. This approach is particularly advantageous in dermatological and pharmaceutical topical products where sensory attributes significantly influence adherence to therapy.

Penetration Enhancer In Transdermal And Topical Formulations

Isopropyl Palmitate functions as a penetration enhancer by temporarily disrupting the stratum corneum lipid bilayer organization, increasing drug flux across the skin barrier. The mechanism involves:

  • Lipid Fluidization: IPP intercalates into stratum corneum lipid domains, increasing membrane fluidity and reducing diffusional resistance 78
  • Partitioning Enhancement: The lipophilic nature of IPP increases the partition coefficient of drugs from the vehicle into the stratum corneum, driving higher drug concentrations at the absorption site 410
  • Solvent Drag Effect: When combined with volatile solvents (ethanol, isopropyl alcohol), IPP remains on the skin surface after solvent evaporation, creating a reservoir effect that sustains drug delivery 4

Quantitative permeation studies indicate that formulations containing 5–10 wt% IPP can increase transdermal flux of lipophilic drugs by 2–5 fold compared to IPP-free controls, with enhancement factors dependent on drug molecular weight and log P 410. For optimal penetration enhancement, IPP should be combined with humectants (propylene glycol, glycerin at 5–15 wt%) to prevent excessive skin dehydration and maintain barrier integrity during chronic use.

Stability Enhancement Mechanisms In Pharmaceutical Formulations

Chemical Stabilization Of Labile Active Ingredients

Isopropyl Palmitate contributes to API stability through multiple mechanisms documented in pharmaceutical patent literature. In formulations containing pyridylaminoacetic acid derivatives for glaucoma treatment, IPP-compatible surfactant systems (polyoxyethylene castor oil at 200–5,000 parts per part API) significantly reduce degradation rates of the active compound 511. The stabilization mechanisms include:

  • Oxidative Protection: IPP's saturated hydrocarbon chain lacks oxidizable double bonds, and its presence in formulations can dilute pro-oxidant species and reduce oxidative degradation of sensitive APIs 5
  • Hydrolytic Shielding: By creating a lipophilic microenvironment around moisture-sensitive drugs, IPP reduces water activity at the molecular level, slowing hydrolysis kinetics 511
  • pH Buffering Capacity: While IPP itself is non-ionic, its ester functionality can participate in hydrogen bonding networks that stabilize pH-sensitive compounds against degradation 11

Accelerated stability studies (40°C/75% RH for 6 months) of IPP-containing formulations demonstrate <5% API degradation compared to 15–25% degradation in IPP-free controls, highlighting the excipient's protective role 511. For maximum stability benefit, IPP should be combined with antioxidants (butylated hydroxytoluene at 0.01–0.1 wt%, vitamin E at 0.1–0.5 wt%) and chelating agents (EDTA at 0.01–0.05 wt%) in a comprehensive stabilization strategy.

Physical Stability And Phase Behavior Control

In emulsion and suspension formulations, Isopropyl Palmitate influences physical stability through its effects on:

  • Ostwald Ripening Suppression: IPP's low water solubility (<0.01 mg/mL) minimizes molecular diffusion through the continuous phase in emulsions, reducing droplet growth rates and extending shelf life 16
  • Crystallization Inhibition: For supersaturated drug solutions or amorphous solid dispersions, IPP can act as a crystallization inhibitor by disrupting nucleation sites and crystal growth kinetics 410
  • Syneresis Prevention: In gel formulations, IPP incorporation (2–5 wt%) reduces water exudation by modifying the gel network structure and water-binding capacity 1

Long-term stability protocols (25°C/60% RH for 24 months) show that IPP-containing emulsions maintain droplet size distributions within ±10% of initial values, compared to ±30–50% changes in formulations using alternative lipid excipients 16. This stability advantage translates to consistent dosing accuracy and product performance throughout the shelf life.

Regulatory Status And Safety Profile For Pharmaceutical Applications

FDA And International Regulatory Recognition

Isopropyl Palmitate enjoys favorable regulatory status across major pharmaceutical markets, facilitating its use in diverse drug delivery applications:

  • FDA Inactive Ingredient Database: IPP is listed for use in oral tablets/capsules (up to 5 wt%), topical preparations (up to 25 wt%), and parenteral formulations (up to 10 wt%) 78
  • EPA Exemption (40 CFR § 180.1001(e)): IPP is exempt from pesticide tolerance requirements when used as a solvent in accordance with good agricultural practice, indicating low toxicity and environmental safety 78
  • Cosmetic Ingredient Review (CIR): Assessed as safe for use in cosmetics at concentrations up to 20%, with no evidence of carcinogenicity, mutagenicity, or reproductive toxicity in comprehensive safety evaluations 78
  • European Pharmacopoeia: Monograph available with specifications for pharmaceutical-grade IPP, including purity requirements (≥95% ester content), acid value (<1.0 mg KOH/g), and heavy metals limits (<10 ppm) 7

The compound's GRAS (Generally Recognized As Safe) status for certain applications and its exemption from food tolerance residue requirements under the Federal Food, Drug, and Cosmetic Act further support its use in pharmaceutical products that may contact food or be ingested 78.

Toxicological Profile And Safety Considerations

Comprehensive toxicological assessments establish IPP's safety profile for pharmaceutical use:

  • Acute Toxicity: Oral LD₅₀ in rats >10 g/kg body weight, indicating very low acute toxicity 78
  • Dermal Irritation: Non-irritating to intact skin in human repeat insult patch tests (HRIPT) at concentrations up to 20% 7
  • Ocular Tolerance: Mild to non-irritating in rabbit Draize tests; suitable for ophthalmic formulations at appropriate concentrations (<1% in final product) 91112
  • Sensitization Potential: Non-sensitizing in guinea pig maximization tests and human studies, with no reports of allergic contact dermatitis in clinical use 78
  • Systemic Exposure: Following dermal application, IPP undergoes rapid esterase-mediated hydrolysis to palmitic acid and isopropanol, both endogenous metabolites with well-characterized safety profiles 78

For pharmaceutical formulation scientists, these safety data support IPP's use across multiple administration routes with minimal risk of adverse effects when used within established concentration ranges. However, formulations intended for chronic use or application to compromised skin should undergo appropriate safety testing to confirm tolerability in the target patient population.

Advanced Applications In Novel Drug Delivery Platforms

Transdermal And Topical Drug Delivery Systems

Isopropyl Palmitate's penetration-enhancing properties and favorable sensory characteristics make it an ideal excipient for advanced transdermal delivery systems. Patent US5eddfe44 and US a9c629f9 describe IPP-based formulations for enhanced drug delivery, demonstrating:

  • Matrix-Type Transdermal Patches: IPP at 5–15 wt% in pressure-sensitive adhesive matrices increases drug loading capacity (up to 20 mg/cm²) and maintains consistent release rates over 24–72 hours 410
  • Microemulsion Systems: IPP as the oil phase (10–30 wt%) combined with non-ionic surfactants (Tween 80, Span 20 at 20–40 wt%) and co-surfactants (ethanol at 10–20 wt%) creates thermodynamically stable microemulsions with droplet sizes <50 nm, enhancing skin permeation of both lipophilic and hydrophilic drugs 410
  • Supersaturated Formulations: IPP-ethanol co-solvent systems (1:2 to 1:5 ratio) enable supersaturation of poorly soluble APIs, achieving 2–10 fold higher drug concentrations than equilibrium solubility, with crystallization inhibited by polymeric stabilizers (hydroxypropyl cellulose, polyvinylpyrrolidone at 1–5 wt%) 410

Clinical translation of these technologies has demonstrated bioequivalence to oral formulations for selected drugs (e.g., NSAIDs, hormones) while reducing systemic side effects and improving patient compliance through once-daily or twice-weekly dosing regimens 410.

Parenteral And Injectable Formulations

In parenteral drug delivery, Isopropyl Palmitate serves as a solubilizing agent and stabilizer for lipophilic drugs requiring injection. Key applications include:

  • Intramuscular Depot Formulations: IPP at 5–20 wt% in oil-based depot injections provides sustained release of lipophilic drugs (e.g., antipsychotics, hormones) over 2–4 weeks through controlled diffusion from the injection site 78
  • Intravenous Lipid Emulsions: IPP as a co-lipid (2–10 wt% of total lipid phase) in parenteral nutrition or drug delivery emulsions improves physical stability and reduces phospholipid requirements, lowering formulation costs 410
  • Subcutaneous Formulations: IPP-based vehicles for subcutaneous administration of biologics and small molecules enhance bioavailability (70–95% compared to 40–60% for aqueous formulations) by facilitating lymphatic uptake and reducing first-pass metabolism 410

Safety considerations for parenteral IPP use include ensuring pharmaceutical-grade purity (≥99%, with peroxide value <5 meq/kg and heavy metals <5 ppm), sterile filtration (0.22 μm), and compatibility testing with primary packaging materials (glass, cyclic olefin copolymer) to prevent extractables/leachables issues 78.

Ophthalmic Drug Delivery Applications

Recent patent literature highlights IPP's role in ophthalmic formulations for glaucoma and ocular hypertension treatment. Patents US728e8a05, US21f08a16, and US b0ace34a describe pharmaceutical preparations containing pyridylaminoacetic acid compounds (EP2 receptor agonists) with IPP

OrgApplication ScenariosProduct/ProjectTechnical Outcomes
Beiersdorf AGCosmetic and dermatological emulsion preparations requiring viscosity modulation and improved spreadability for topical application.Emulsion-based Dermatological PreparationsIsopropyl palmitate enables viscosity adjustment without traditional thickeners or gelling agents, providing rheological control in emulsion formulations.
Tioga Research Inc.Transdermal and topical drug delivery systems for lipophilic drugs requiring enhanced skin penetration and sustained release over 24-72 hours.Transdermal Drug Delivery SystemsFormulations containing 5-12 wt% isopropyl palmitate combined with C2-4 alcohols achieve enhanced drug solubilization, improved skin permeation (2-5 fold increase in transdermal flux), and optimized bioavailability for poorly water-soluble APIs.
Santen Pharmaceutical Co. Ltd.Ophthalmic preparations for treatment and prevention of glaucoma and ocular hypertension requiring precise dosing and enhanced drug stability.Ophthalmic Glaucoma Treatment FormulationsUltra-low concentration formulations (0.0003-0.01% w/v) of pyridylaminoacetic acid compounds with isopropyl palmitate-compatible surfactant systems demonstrate excellent intraocular pressure lowering effects while maintaining ocular tolerability and API stability.
EcoSMART Technologies Inc.Agricultural pesticide formulations requiring safe, non-toxic solvents with regulatory exemptions for food crop applications and organic farming systems.Pesticidal Formulations with Isopropyl PalmitateIsopropyl palmitate serves as an EPA-exempt solvent and synergist in pesticidal compositions, providing regulatory advantages including exemption from tolerance requirements and potential use in organic farming applications.
Reference
  • Isopropyl palmitate as a viscosity-regulating lipid in cosmetic or dermatological emulsion preparations
    PatentWO2012120002A3
    View detail
  • Pharmaceutical excipient, method for its preparation and use thereof
    PatentInactiveEP2384742A1
    View detail
  • Pharmaceutical excipient, method for its preparation and use thereof
    PatentInactiveUS20120288529A1
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png